Abstract 951P
Background
Preventing post-operative recurrence and metastasis has become a critical factor in determining the success of hepatectomy for HCC patients (pts). However, the optimal treatment strategy for adjuvant therapy is still under debate. The aim of this study was to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anlotinib and TQB2450 (PD-L1 monoclonal antibody) as adjuvant therapy for pts with HCC at high risk of recurrence after hepatectomy.
Methods
Pts diagnosed as HCC with one or more of the high risk factors after hepatectomy were eligible. Eligible pts received FOLFOX-HAIC (1 cycle) within 1 months after hepatectomy, and on the 2nd day after HAIC, anlotinib (10mg, 4 cycles or 8 cycles) and TQB2450 (1200mg, 4 cycles) were given. The primary endpoint was disease free survival (DFS). Secondary endpoints included overall survival (OS), time to recurrence (TTR) and safety.
Results
At April 18 2023, 72 pts were enrolled and 68 were available to be analyzed. Among them, 34 pts have completed treatment, 26 pts were still on treatment, 8 pts discontinued treatmentearly due to adverse events (AE). 70.6% with liver cirrhosis, 67.7% with MVI, 33.8% with preoperative intrahepatic lesions≥8cm, 7.4% with≥3tumor lesions, 2.9% with tumor thrombus, and 2.9% with preoperative rupture of the tumor or invasion of adjacent organs. At median follow-up of 6.0 (range 0.9-15.1) months, 1 pts relapsed (DFS was 10.87 months).1-year DFS rate was 85.7%, and the longest DFS was over 16.92 months in all pts. The median DFS and OS were not available. Safety profile indicated that 67 pts (98.5%) experienced treatment-related adverse events (TRAEs), and common grade 3 TRAEs included hypertension (8.8%), neutropenia (7.4%) and thrombocytopenia (5.9%).
Conclusions
HAIC combined with anlotinib and TQB2450 as adjuvant therapy for pts with HCC at high risk of recurrence after primary hepatectomy exhibits promising prognosis and tolerable safety profile, and further follow-up is needed for this study to obtain mature data.
Clinical trial identification
NCT05311319.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chia-Tai Tianqing Pharmaceutical Group Co Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18